Back to Search Start Over

Astersaponin I from Aster koraiensis is a natural viral fusion blocker that inhibits the infection of SARS-CoV-2 variants and syncytium formation.

Authors :
Kim TY
Kim JY
Kwon HC
Jeon S
Lee SJ
Jung H
Kim S
Jang DS
Lee CJ
Source :
Antiviral research [Antiviral Res] 2022 Dec; Vol. 208, pp. 105428. Date of Electronic Publication: 2022 Oct 15.
Publication Year :
2022

Abstract

The continuous emergence of SARS-CoV-2 variants prolongs COVID-19 pandemic. Although SARS-CoV-2 vaccines and therapeutics are currently available, there is still a need for development of safe and effective drugs against SARS-CoV-2 and also for preparedness for the next pandemic. Here, we discover that astersaponin I (AI), a triterpenoid saponin in Aster koraiensis inhibits SARS-CoV-2 entry pathways at the plasma membrane and within the endosomal compartments mainly by increasing cholesterol content in the plasma membrane and interfering with the fusion of SARS-CoV-2 envelope with the host cell membrane. Moreover, we find that this functional property of AI as a fusion blocker enables it to inhibit the infection with SARS-CoV-2 variants including the Alpha, Beta, Delta, and Omicron with a similar efficacy, and the formation of syncytium, a multinucleated cells driven by SARS-CoV-2 spike protein-mediated cell-to-cell fusion. Finally, we claim that the triterpene backbone as well as the attached hydrophilic sugar moieties of AI are structurally important for its inhibitory activity against the membrane fusion event. Overall, this study demonstrates that AI is a natural viral fusion inhibitor and proposes that it can be a broad-spectrum antiviral agent against current COVID-19 pandemic and future outbreaks of novel viral pathogens.<br />Competing Interests: Declaration of competing interest The authors declare no conflict of interests.<br /> (Copyright © 2022 Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1872-9096
Volume :
208
Database :
MEDLINE
Journal :
Antiviral research
Publication Type :
Academic Journal
Accession number :
36252824
Full Text :
https://doi.org/10.1016/j.antiviral.2022.105428